Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes
Sebastian Kreil(Heidelberg University), Andreas Reiter(Heidelberg University), Anna Lübking(Skåne University Hospital), Andreas Hochhaus(Jena University Hospital), Nicholas C.P. Cross(University of Southampton), Peter Martin(Northwestern University), Martin Bommer(University Hospital Ulm), Ekkehard Eigendorff(Jena University Hospital), Wolf‐Karsten Hofmann(Heidelberg University), Lionel Adès(Délégation Paris 7), Mark Ethell(Royal Marsden NHS Foundation Trust), Frank Stegelmann(University Hospital Ulm)
Cited by 35
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k